All In Biotech

Drug Trial Radar · NCT00261846

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

A Phase 1/2 Study Of Bosutinib (Ski-606) In Philadelphia Chromosome Positive Leukemias

Last checked: Nov 20, 2026Latest source record: Jul 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

571

Actual

Start

Jan 18, 2006

Primary completion

Sep 25, 2009

Study completion Aug 6, 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, continuous daily dosing, two-part safety and efficacy study of SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). Part 1 is a dose-escalation study in chronic phase Chronic Myelogenous Leukemia (CML) subjects to establish the maximum tolerated dose (MTD) in this subject population. Part 2 has begun after the completion of Part 1 and after a dose has been established for the compound in chronic phase subjects. Part 2 is a study of the the efficacy of 500mg daily oral SKI-606 (bosutinib) in patients with all phases of Ph+ CML and Ph+ Acute Lymphocytic Leukemia (ALL). The protocol will test the hypotheses that oral daily dosing of bosutinib at 500 mg will attain (1) Major Cytogenetic Response (MCyR) in chronic phase CML patients and (2) Overall Hematological Response (OHR) in advanced leukemia patients. Each phase of the disease will be evaluated as a separate cohort.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • BosutinibDrug

    Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component. Part 2, 500 mg oral, continuous, daily dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Part 1 Baseline up to Day 28
  2. Maximum Tolerated Dose (MTD)Time frame: Part 1 Baseline up to Day 28
  3. Maximum Observed Plasma Concentration (Cmax) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
  4. Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
  5. Plasma Decay Half-Life (t1/2) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC(0-48)] - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
  7. Area Under the Concentration-Time Curve (AUC) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
  8. Apparent Oral Clearance (CL/F) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
  9. Apparent Volume of Distribution (Vz/F) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
  10. Maximum Observed Plasma Concentration at Steady State (Cmax,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
  11. Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
  12. Plasma Decay Half-Life at Steady State (t1/2,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
  13. Area Under the Concentration-Time Curve at Steady State (AUCss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
  14. Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
  15. Accumulation Ratio (R)Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 and Day 15
  16. Percentage of Participants With MCyR at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2Time frame: Week 24

Locations

111 sites in 27 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • HealthONE Presbyterian

    Denver, Colorado

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • Emory Clinic

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Winship Cancer Institute

    Atlanta, Georgia

  • Oncology Specialists, S.C.

    Niles, Illinois

  • Indiana Blood and Marrow Transplantation

    Indianapolis, Indiana

  • LSU Health Sciences Center

    Shreveport, Louisiana

  • University Of Maryland Medical Center

    Baltimore, Maryland

  • University Of Maryland

    Baltimore, Maryland

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Hudson Valley Hematology and Oncology Associates

    Hawthorne, New York

  • Westchester Oncology Hematology Group, P.C.

    Hawthorne, New York

  • Westchester Oncology Hematology, Group, P.C.

    Hawthorne, New York

  • New York Presbyterian Hospital

    New York, New York

  • New York Presbyterian Hospital

    New York, New York

  • University of Rochester Cancer Center Pharmacy

    Rochester, New York

  • University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center

    Rochester, New York

  • University of Rochester Medical Center

    Rochester, New York

  • University of Rochester-James P. Wilmot Cancer Center

    Rochester, New York

  • University of Rochester

    Rochester, New York

  • Westchester Medical Center

    Valhalla, New York

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • The University of Texas

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Hospital Britanico

    Buenos Aires, Argentina

  • Academia Nacional de Medicina-Instituto de Investigaciones Hematologicas

    Buenos Aires, Argentina

  • Instituto Medico Especializado Alexander Fleming

    Buenos Aires, Argentina

  • Clinica del Sol

    Buenos Aires, Argentina

  • Centro Medico S.A.

    Corrientes, Argentina

  • Hospital Jose Ramon Vidal

    Corrientes, Argentina

  • Hospital universitario austral

    Pcia de Buenos Aires, Argentina, Argentina

  • Hospital Italiano de la Plata

    La Plata, Buenos Aires, Argentina

  • Institute of Medical and Veterinary Science

    Adelaide, Australia

  • Department of Clinical Haematology and Bone Marrow Transplantation

    Melbourne, Australia

  • Royal Brisbane and Women's Hospital

    Queensland, Australia

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.